Clinical Trial Update: Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. [Phase 2]

View source ↗

Summary

A phase 2 prospective open-label single-arm trial evaluating hetrombopag for lower-risk myelodysplastic syndromes with thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Tongji Hospital | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN